Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1
Patients with diabetic kidney disease or liver disease should use semaglutide cautiously, as the drug is cleared partly through the kidneys
What's New: July 2026 Update TRIUMPH-4 confirmed: Retatrutide 28.7% weight loss in Phase 3 (December 2025) final data, not preliminary TRIUMPH-1 CONFIRMED (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients without diabetes pivotal trial met all primary endpoints Availability unchanged: Retatrutide still investigational, no FDA approval until late 2027 at earliest Tirzepatide still the best available option: 22.5% weight loss, FDA-approved, available today TRANSCEND-T2D-1 confirmed (June 2026): -2.0% HbA1c and 16.8% weight loss in type 2 diabetes patients a separate diabetes-specific Phase 3 program NDA timeline on track: industry estimates continue to expect Q4 2026 filing, following TRIUMPH-1's positive readout Introduction The evolution of weight loss medications has progressed rapidly from single-agonist drugs to multi-agonist approaches
Customers benefit from the expertise of registered nurses who prioritize individual well-being, making sustained energy and overall health more accessible
Alternatives like Mounjaro, Wegovy, and compounded tirzepatide offer new opportunities to achieve weight loss and health goals
US$ 22.44
US$ 25.84
US$ 28.11
